Cargando…

Trends in add-on medications following metformin monotherapy for type 2 diabetes

BACKGROUND: Although metformin is generally universally recommended as a first-line pharmacologic therapy for most people living with type 2 diabetes, second-line and third-line choices can require a tailored approach to achieve optimal blood glucose and glycated hemoglobin levels. OBJECTIVE: To exa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swart, Elizabeth CS, Neilson, Lynn M, Munshi, Kiraat D, Peasah, Samuel K, Henderson, Rochelle, Good, Chester B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373027/ https://www.ncbi.nlm.nih.gov/pubmed/36282929 http://dx.doi.org/10.18553/jmcp.2022.28.11.1253

Ejemplares similares

Trends in utilization and costs of migraine medications, 2017–2020
por: Nguyen, Jennifer L., et al.
Publicado: (2022)

Real-World Use and Outcomes of Oral Antiplatelets Among Patients with Acute Coronary Syndrome: A Retrospective Cohort Study
por: Peasah, Samuel K., et al.
Publicado: (2021)

Twelve month oral contraceptive pill prescriptions: Role of policy mandates on utilization
por: Peasah, Samuel K., et al.
Publicado: (2021)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Identifying Outcome Measures for Coronary Artery Disease Value-Based Contracting Using the Delphi Method
por: Neilson, Lynn M., et al.
Publicado: (2019)

Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement
por: Peasah, Samuel K, et al.
Publicado: (2023)

Impact of a diabetes remote monitoring program on medication adherence
por: Munshi, Kiraat D, et al.
Publicado: (2021)

Predictors of HbA(1c) treatment response to add-on medication following metformin monotherapy: a population-based cohort study
por: Tan, Wei Ying, et al.
Publicado: (2023)

The Effect of Florida Medicaid’s State-Mandated Formulary Provision on Prescription Drug Use and Health Plan Costs in a Medicaid Managed Care Plan
por: Munshi, Kiraat D., et al.
Publicado: (2018)

Economic assessment of changes to an existing medication therapy management program of a large regional health plan
por: Peasah, Samuel K, et al.
Publicado: (2021)

Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting
por: Swart, Elizabeth C S, et al.
Publicado: (2020)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study
por: Yu, Shengsheng, et al.
Publicado: (2016)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
por: LaFratte, Christopher, et al.
Publicado: (2023)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial
por: Sartore, Giovanni, et al.
Publicado: (2021)

Ticagrelor versus clopidogrel for recurrent myocardial infarction: An outcomes-based agreement
por: Peasah, Samuel K., et al.
Publicado: (2023)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial
por: Lian, Fengmei, et al.
Publicado: (2015)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
por: Lim, Phei C., et al.
Publicado: (2015)

Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure
por: Nauck, Michael A, et al.
Publicado: (2010)

Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality
por: Tizazu, Anteneh Mehari, et al.
Publicado: (2019)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder
por: Berlant, Jeffrey L
Publicado: (2004)

Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy: A prospective study
por: Liu, Yu-Tse, et al.
Publicado: (2020)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma
por: Valtorta, Silvia, et al.
Publicado: (2021)

Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics
por: Guarnaccia, Laura, et al.
Publicado: (2022)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Preventive Metformin Monotherapy Medication Prescription, Redemption and Socioeconomic Status in Hungary in 2018–2019: A Cross-Sectional Study
por: Nagy, Csilla, et al.
Publicado: (2021)

Effectiveness of dose-escalated topiramate monotherapy and add-on therapy in neurosurgery-related epilepsy: A prospective study: Erratum
Publicado: (2021)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
por: Philip, Elizabeth, et al.
Publicado: (2013)

Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder
por: Hebrani, Paria, et al.
Publicado: (2015)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pln9dvje5cg5etba62efqrh5gb